VACCITECH PLC (VACC) Fundamental Analysis & Valuation

NASDAQ:VACC • US91864C1071

Current stock price

5 USD
+0.51 (+11.36%)
At close:
4.9 USD
-0.1 (-2%)
After Hours:

This VACC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. VACC Profitability Analysis

1.1 Basic Checks

  • In the past year VACC has reported negative net income.
  • In the past year VACC has reported a negative cash flow from operations.
VACC Yearly Net Income VS EBIT VS OCF VS FCFVACC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 0 -10M -20M -30M -40M -50M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -22.32%, VACC belongs to the top of the industry, outperforming 80.10% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -25.29%, VACC belongs to the top of the industry, outperforming 83.25% of the companies in the same industry.
Industry RankSector Rank
ROA -22.32%
ROE -25.29%
ROIC N/A
ROA(3y)-17.03%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VACC Yearly ROA, ROE, ROICVACC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 0 200 400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for VACC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VACC Yearly Profit, Operating, Gross MarginsVACC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 0 -5K -10K -15K

8

2. VACC Health Analysis

2.1 Basic Checks

  • VACC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • VACC has more shares outstanding than it did 1 year ago.
  • There is no outstanding debt for VACC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VACC Yearly Shares OutstandingVACC Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 10M 20M 30M
VACC Yearly Total Debt VS Total AssetsVACC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

  • An Altman-Z score of 3.18 indicates that VACC is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 3.18, VACC is in the better half of the industry, outperforming 76.29% of the companies in the same industry.
  • VACC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.18
ROIC/WACCN/A
WACC9.06%
VACC Yearly LT Debt VS Equity VS FCFVACC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 50M 100M 150M 200M 250M

2.3 Liquidity

  • VACC has a Current Ratio of 15.26. This indicates that VACC is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of VACC (15.26) is better than 88.06% of its industry peers.
  • A Quick Ratio of 15.26 indicates that VACC has no problem at all paying its short term obligations.
  • VACC has a better Quick ratio (15.26) than 88.23% of its industry peers.
Industry RankSector Rank
Current Ratio 15.26
Quick Ratio 15.26
VACC Yearly Current Assets VS Current LiabilitesVACC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 50M 100M 150M 200M

2

3. VACC Growth Analysis

3.1 Past

  • VACC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -4723.33%.
  • The Revenue for VACC has decreased by -58.53% in the past year. This is quite bad
  • Measured over the past years, VACC shows a very strong growth in Revenue. The Revenue has been growing by 86.87% on average per year.
EPS 1Y (TTM)-4723.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-251.22%
Revenue 1Y (TTM)-58.53%
Revenue growth 3Y86.87%
Revenue growth 5YN/A
Sales Q2Q%-98.04%

3.2 Future

  • The Earnings Per Share is expected to decrease by -98.17% on average over the next years. This is quite bad
  • Based on estimates for the next years, VACC will show a very negative growth in Revenue. The Revenue will decrease by -60.57% on average per year.
EPS Next Y-1733.53%
EPS Next 2Y-304.24%
EPS Next 3Y-153.1%
EPS Next 5Y-98.17%
Revenue Next Year-95.74%
Revenue Next 2Y-84.84%
Revenue Next 3Y-75.62%
Revenue Next 5Y-60.57%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
VACC Yearly Revenue VS EstimatesVACC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M
VACC Yearly EPS VS EstimatesVACC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0 -0.5 -1 -1.5 -2

0

4. VACC Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for VACC. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VACC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VACC Price Earnings VS Forward Price EarningsVACC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VACC Per share dataVACC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • VACC's earnings are expected to decrease with -153.10% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-304.24%
EPS Next 3Y-153.1%

0

5. VACC Dividend Analysis

5.1 Amount

  • VACC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

VACC Fundamentals: All Metrics, Ratios and Statistics

VACCITECH PLC

NASDAQ:VACC (11/6/2023, 8:00:01 PM)

After market: 4.9 -0.1 (-2%)

5

+0.51 (+11.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-09
Earnings (Next)N/A
Inst Owners38.61%
Inst Owner Change-13.85%
Ins Owners26.92%
Ins Owner Change0%
Market Cap192.73M
Revenue(TTM)13.42M
Net Income(TTM)-54.93M
Analysts81.82
Price Target9.5 (90%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.31%
Min EPS beat(2)-11.12%
Max EPS beat(2)6.51%
EPS beat(4)2
Avg EPS beat(4)32.49%
Min EPS beat(4)-30.8%
Max EPS beat(4)165.36%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-57.42%
Min Revenue beat(2)-69.41%
Max Revenue beat(2)-45.42%
Revenue beat(4)1
Avg Revenue beat(4)-11.6%
Min Revenue beat(4)-69.41%
Max Revenue beat(4)91.15%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-24.49%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.13%
EPS NY rev (1m)0%
EPS NY rev (3m)2.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)400%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.36
P/FCF N/A
P/OCF N/A
P/B 0.89
P/tB 1.08
EV/EBITDA N/A
EPS(TTM)-1.45
EYN/A
EPS(NY)-1.91
Fwd EYN/A
FCF(TTM)-0.73
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS0.35
BVpS5.63
TBVpS4.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -22.32%
ROE -25.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-17.03%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 174.45%
Cap/Sales 63.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.26
Quick Ratio 15.26
Altman-Z 3.18
F-Score2
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)156.82%
Cap/Depr(5y)N/A
Cap/Sales(3y)149.12%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4723.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-251.22%
EPS Next Y-1733.53%
EPS Next 2Y-304.24%
EPS Next 3Y-153.1%
EPS Next 5Y-98.17%
Revenue 1Y (TTM)-58.53%
Revenue growth 3Y86.87%
Revenue growth 5YN/A
Sales Q2Q%-98.04%
Revenue Next Year-95.74%
Revenue Next 2Y-84.84%
Revenue Next 3Y-75.62%
Revenue Next 5Y-60.57%
EBIT growth 1Y-82.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1689.94%
EBIT Next 3Y-191.11%
EBIT Next 5YN/A
FCF growth 1Y39.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.71%
OCF growth 3YN/A
OCF growth 5YN/A

VACCITECH PLC / VACC Fundamental Analysis FAQ

What is the fundamental rating for VACC stock?

ChartMill assigns a fundamental rating of 3 / 10 to VACC.


What is the valuation status for VACC stock?

ChartMill assigns a valuation rating of 0 / 10 to VACCITECH PLC (VACC). This can be considered as Overvalued.


What is the profitability of VACC stock?

VACCITECH PLC (VACC) has a profitability rating of 1 / 10.